首页> 美国卫生研究院文献>Journal of Lipid Research >Abolished synthesis of cholic acid reduces atherosclerotic development in apolipoprotein E knockout mice
【2h】

Abolished synthesis of cholic acid reduces atherosclerotic development in apolipoprotein E knockout mice

机译:取消胆酸合成可减少载脂蛋白E基因敲除小鼠的动脉粥样硬化发展

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

To investigate the effects of abolished cholic acid (CA) synthesis in the ApoE knockout model [apolipoprotein E (apoE) KO],a double-knockout (DKO) mouse model was created by crossbreeding Cyp8b1 knockout mice (Cyp8b1 KO), unable to synthesize the primary bile acid CA, with apoE KO mice. After 5 months of cholesterol feeding, the development of atherosclerotic plaques in the proximal aorta was 50% less in the DKO mice compared with the apoE KO mice. This effect was associated with reduced intestinal cholesterol absorption, decreased levels of apoB-containing lipoproteins in the plasma, enhanced bile acid synthesis, reduced hepatic cholesteryl esters, and decreased hepatic activity of ACAT2. The upregulation of Cyp7a1 in DKO mice seemed primarily caused by reduced expression of the intestinal peptide FGF15. Treatment of DKO mice with the farnesoid X receptor (FXR) agonist GW4064 did not alter the intestinal cholesterol absorption, suggesting that the action of CA in this process is confined mainly to formation of intraluminal micelles and less to its ability to activate the nuclear receptor FXR. Inhibition of CA synthesis may offer a therapeutic strategy for the treatment of hyperlipidemic conditions that lead to atherosclerosis.
机译:为了研究废除的胆酸(CA)合成在ApoE基因敲除模型[载脂蛋白E(apoE)KO]中的作用,通过杂交Cyp8b1基因敲除小鼠(Cyp8b1 KO)创建了双重基因敲除(DKO)小鼠模型。初级胆汁酸CA,以及apoE KO小鼠。胆固醇喂养5个月后,与apoE KO小鼠相比,DKO小鼠的主动脉近端动脉粥样硬化斑块的形成减少了50%。这种作用与降低肠道胆固醇吸收,降低血浆中含apoB的脂蛋白水平,增强胆汁酸合成,降低肝胆固醇酯以及降低ACAT2的肝活性有关。 DKO小鼠中Cyp7a1的上调似乎主要是由于肠肽FGF15的表达减少所致。用法尼醇X受体(FXR)激动剂GW4064处理DKO小鼠不会改变肠道胆固醇的吸收,这表明CA在此过程中的作用主要限于腔内微团的形成,而其激活核受体FXR的能力则较小。 。抑制CA合成可以为治疗导致动脉粥样硬化的高脂血症病症提供治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号